Status:
UNKNOWN
Head-to-head Comparison Between [18F]-FDG PET/CT and PET/MRI in Lymphomas
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
PET/MRI
Eligibility:
All Genders
15-80 years
Brief Summary
Investigating the performance of 18F-FDG PET/CT and PET/MRI in lymphomas
Detailed Description
In this study investigators evaluated Nodal and Extranodal Lymphoma Lesions uptake by 18F-FDG PET (PET/CT and PET/MR). Prior to treatment, all patients will undergo whole-body 18F-FDG PET/CT and PET/M...
Eligibility Criteria
Inclusion
- pathologically diagnosed as lymphoma; Written informed consent for receiving PET/MRI after PET/CT examinations. cancer planned chemotherapy or immunotherapy scheme. expected survival ≥ 12 weeks
Exclusion
- cannot lie supine for half an hour; refuse to join the clinical researcher; severe liver or kidney dysfunction pregnancy or lactation
Key Trial Info
Start Date :
October 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 15 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05390632
Start Date
October 15 2019
End Date
December 15 2023
Last Update
March 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital
Beijing, Card Holder's Billing State / Province, China, 100142